Erasca Q2 net loss $63.2M; cash $460M; in-licenses RAS drugs, begins Phase 3

Erasca, Inc.

2024-Q2 EPS reported -$0.53

Net loss $63.2M ($0.29/share) vs $31.8M ($0.21/share) YOY; R&D $33M including $22.5M in-license payments.
Cash, equivalents & securities $460.2M (up from $322M Dec 2023); runway into H1 2027.
In-licensed pan-RAS glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001; IND filings H1 2025 and Q1 2025.
Initiated SEACRAFT-2 Phase 3 trial for naporafenib + trametinib in NRASm melanoma; randomized data 2025.
Phase 1b combo data in RAS Q61X tumors expected Q4 2024; initial monotherapy data for ERAS-0015/4001 in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.